Mission Bio Transfers First Tapestri GMP-Ready CGT Assay to Avance Biosciences

 Mission Bio Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis developed by UCSF researcher Adam Abate, announced today the first tech transfer of a clinical trial-ready cell and gene therapy (CGT) assay from its Tapestri Platform to Avance Biosciences, Inc., a leading-edge CRO based in Houston, Texas, to assess transduction efficiency for an autologous cell therapy currently under development. 

MORE